**Converting HTML to Markdown**

The user wants a markdown version of an HTML snippet, which seems like documentation for an API endpoint. I'll remove the HTML tags and transform the content into proper markdown format. This will include using markdown syntax for headings (e.g. #, ## for titles), code blocks for example codes (for JS, curl, Python), and tables for things like parameters. I'll make sure it's easy to read and structured properly in markdown style. Looks like a fairly straightforward format conversion.

**Converting API Doc to Markdown**

I’ll convert the API documentation into markdown format. There’s a title, the endpoint in code format, followed by a “Try It” section, which I'll remove. Then, code examples like JavaScript are presented in a code block. I'll include the sample response and the Authorization and Query Parameters sections. For the query parameters, I’ll structure them as a markdown table with necessary details like type, required, description, etc. I’ll make sure everything looks neat and correctly structured in markdown format!

**Markdown Version for API Documentation**

I’m converting this API documentation into markdown format. I’ll keep the API overview, request method, and endpoint applied. Then, I’ll create tables for authorization and query parameters. With the code snippets (like JavaScript), I’ll use proper markdown formatting for code blocks. Lastly, I’ll format the response example and fields listed, making it easy to read. No external tools needed here, just plain markdown - this seems like a pretty straightforward task!


Thought for 11 seconds


````markdown
# GET Analyst Insights

Get the qualitative summaries of Analyst Research Reports

---

## HTTP Request

`GET https://api.benzinga.com/api/v1/analyst/insights`

---

## Authorization

| Name  | Type   | In    | Required | Description       |
| ----- | ------ | ----- | -------- | ----------------- |
| token | string | query | yes      | Your API token.   |

---

## Query Parameters

| Parameter        | Type         | Default | Description                                                                                   |
| ---------------- | ------------ | ------- | --------------------------------------------------------------------------------------------- |
| `page`           | integer      | 1       | Page number for pagination.                                                                   |
| `pageSize`       | integer      | 10      | Number of items per page.                                                                     |
| `symbols`        | string       |         | Stock ticker symbols separated by commas.                                                     |
| `analyst`        | string       |         | One or more analyst IDs separated by commas.                                                  |
| `rating_id`      | string       |         | One or more rating IDs separated by commas.                                                   |
| `search_keys_type` | enum<string> |         | Key to query by firm (options: `firm_id`, `firm`).                                            |
| `search_keys`    | string       |         | The corresponding identifier value when using `search_keys_type`.                             |

---

## Example

### JavaScript

```javascript
const options = { method: 'GET' };

fetch('https://api.benzinga.com/api/v1/analyst/insights', options)
  .then(response => response.json())
  .then(response => console.log(response))
  .catch(err => console.error(err));
````

---

## Sample Response (200 OK)

```json
{
  "action": "Reiterates",
  "analyst_insights": "This morning, HC Wainwright & Co. reiterated their Buy rating on Cybin's stock with a price target of $5.0000.\n\n- **Advancing Clinical Pipeline:** Cybin is making significant strides in its clinical development programs, with a focus on progressing CYB003 for major depressive disorder (MDD) and CYB004 for generalized anxiety disorder (GAD) into the next phases of clinical trials. The company plans to report three-month efficacy data from a Phase 2 trial of CYB003 and is preparing for an end-of-Phase 2 meeting with the FDA, demonstrating a clear path forward for these programs.\n\n- **Positive Valuation Model:** HC Wainwright & Co. employs a discounted cash flow (DCF)-based valuation methodology, assigning a 55% probability of success for CYB003 in treating MDD and a 45% probability for CYB004 in treating GAD. These probabilities, along with planned equity raises and a conservative discount rate, support a $5 price target, suggesting confidence in Cybin’s potential market value and future revenue generation capabilities from these treatments.\n\n- **Strategic Regulatory Milestones:** Cybin has received FDA clearance to initiate a Phase 2a trial evaluating CYB004 in GAD, expected to start in 1Q24. This clearance, coupled with the planned end-of-Phase 2 meeting for CYB003, indicates regulatory progress and positions Cybin favorably for advancing its therapeutic candidates through the clinical development process, ultimately enhancing shareholder value.",
  "date": "2024-02-15",
  "firm": "HC Wainwright & Co.",
  "firm_id": "5c383d9b0448fc02d76b09d5",
  "id": "65ce4cb3ba47d164700176bf",
  "pt": "5.0000",
  "rating": "Buy",
  "rating_id": "65ce4c5d0ebf29000101f29b",
  "security": {
    "cik": "",
    "exchange": "AMEX",
    "isin": "",
    "name": "Cybin",
    "symbol": "CYBN"
  },
  "updated": 1708018876
}
```

---

## Response Fields

| Field               | Type    | Description                                                |
| ------------------- | ------- | ---------------------------------------------------------- |
| `action`            | string  | Analyst's action on the stock (e.g., Maintains, Upgrades). |
| `analyst_insights`  | string  | Detailed insights from the analyst.                        |
| `date`              | string  | Date of the analyst insight (YYYY-MM-DD).                  |
| `firm`              | string  | Name of the firm providing the insight.                    |
| `firm_id`           | string  | Unique identifier for the firm.                            |
| `id`                | string  | Unique identifier for the analyst insight.                 |
| `pt`                | string  | Price target given by the analyst.                         |
| `rating`            | string  | Rating provided by the analyst.                            |
| `rating_id`         | string  | Unique identifier for the rating.                          |
| `security`          | object  | Security details for which the insight is provided.        |
| `security.cik`      | string  | CIK of the security.                                       |
| `security.exchange` | string  | Exchange of the security.                                  |
| `security.isin`     | string  | ISIN of the security.                                      |
| `security.name`     | string  | Name of the security.                                      |
| `security.symbol`   | string  | Symbol of the security.                                    |
| `updated`           | integer | UNIX timestamp of when the insight was last updated.       |

```
```
